{"created":"2023-05-15T16:41:54.277887+00:00","id":16702,"links":{},"metadata":{"_buckets":{"deposit":"a1bd9a82-5d45-4823-b3dc-d404ebbaa1c4"},"_deposit":{"created_by":2,"id":"16702","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"16702"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00016702","sets":["29:30"]},"author_link":["64310","64312","64309","64311","64306","64307","64304","64305","64308"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-04","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"7","bibliographicPageEnd":"535","bibliographicPageStart":"527","bibliographicVolumeNumber":"48","bibliographic_titles":[{"bibliographic_title":"Internal Medicine"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background and Objective The growing problem of drug resistance among respiratory pathogens in community-acquired pneumonia (CAP), particularly Streptococcus pneumoniae, (S. pneumoniae) has complicated initial empiric therapy of CAP. This study was undertaken to evaluate the efficacy and tolerability of a 3-day course of azithromycin in adults with mild to moderately severe CAP, and to determine whether in vitro macrolide resistance among strains of S. pneumoniae is related to clinical efficacy/failure. Methods An open-label, non-comparative study was undertaken at 3 university-affiliated hospitals in Japan. Patients were eligible if they were 18 years or older and had mild or moderately severe CAP. All patients received azithromycin 500 mg/day for three days, and clinical and microbiological responses were evaluated 1 and 2 weeks after initiating therapy. Results A total of 78 patients received the study medication, 59 of whom had sufficient data available for efficacy analysis. Overall, a good clinical response with azithromycin was achieved in 49 patients (83.1%) and a microbiological response was achieved in 78.3%. Azithromycin resistance, based on CLSI criteria, was demonstrated in 85.7% (12/14) of S. pneumoniae isolates, and the presence of ermB genes was found in 50.0% (7/14). However, among patients in whom S. pneumoniae was isolated (n=17), a good clinical response was achieved in 76.5% (13/17), and the microbiological response rate was 64.3% (9/14). Furthermore, 6 of 7 patients in whom high-level resistance was documented (MICs >256 μg/mL and carrying ermB genes) exhibited good clinical responses. Azithromycin was well tolerated; adverse events, mainly of a gastrointestinal nature, were recorded in 6 patients (7.7%). Conclusion Most patients responed well to azithromycin, indicating that azithromycin might be clinically effective for the treatment of CAP with macrolide-resistant S. pneumoniae. However, a larger study is necessary to prove the efficacy against macrolide-resistant S. pneumoniae.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Internal Medicine, vol.48(7), pp.527-535; 2009","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本内科学会"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2169/internalmedicine.48.1482","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright (c) 2009 (社)日本内科学会"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"09182918","subitem_source_identifier_type":"ISSN"}]},"item_2_text_62":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"The Japanese Society of Internal Medicine"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yanagihara, Katsunori"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Izumikawa, Koichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Higa, Futoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tateyama, Masao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tokimatsu, Issei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hiramatsu, Kazufumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fujita, Jiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kadota, Jun-ichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kohno, Shigeru"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-23"}],"displaytype":"detail","filename":"IM_48_7_527.pdf","filesize":[{"value":"686.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"IM_48_7_527.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/16702/files/IM_48_7_527.pdf"},"version_id":"9deb9265-772a-49ca-9258-747f3850d090"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"community-acquired pneumonia","subitem_subject_scheme":"Other"},{"subitem_subject":"azithromycin","subitem_subject_scheme":"Other"},{"subitem_subject":"macrolide resistance","subitem_subject_scheme":"Other"},{"subitem_subject":"Streptococcus pneumoniae","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Efficacy of Azithromycin in the Treatment of Community-acquired Pneumonia, Including Patients with Macrolide-Resistant Streptococcus pneumoniae Infection","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Efficacy of Azithromycin in the Treatment of Community-acquired Pneumonia, Including Patients with Macrolide-Resistant Streptococcus pneumoniae Infection"}]},"item_type_id":"2","owner":"2","path":["30"],"pubdate":{"attribute_name":"公開日","attribute_value":"2009-12-04"},"publish_date":"2009-12-04","publish_status":"0","recid":"16702","relation_version_is_last":true,"title":["Efficacy of Azithromycin in the Treatment of Community-acquired Pneumonia, Including Patients with Macrolide-Resistant Streptococcus pneumoniae Infection"],"weko_creator_id":"2","weko_shared_id":2},"updated":"2023-05-15T19:20:10.070301+00:00"}